pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases.

LOCATION

  • Atlanta, GA, USA

  • Brisbane, , Australia

    • THERAPEUTIC AREAS

  • Inflammatory Disease

  • Rare Diseases

    • WEBSITE

    https://www.celtaxsys.com

    CAREER WEBSITE

    None

    SOCIAL MEDIA

    INVESTORS

    domain-associates georgia-research-alliance-venture-fund lumira-ventures lumira-ventures masters-capital-management rmi-partners

    PRESS RELEASES


    Nov 12, 2021


    Oct 22, 2018

    Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference  


    Oct 11, 2018

    Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference


    Oct 11, 2018

    Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference


    Aug 2, 2018

    Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients


    For More Press Releases
    Google Analytics Alternative